volume 271, issue 1-2, P181-187 2004
DOI: 10.1016/j.ijpharm.2003.11.002
View full text
|
|
Share

Abstract: The use of doxorubicin in treating prostate cancer is limited by its systemic toxicities especially cardiotoxicity and immunosuppression. Prodrugs that reduce the systemic exposure of doxorubicin are believed to provide a safety advantage. A prodrug of doxorubicin which contains a peptide sequence that can be recognized by prostate-specific antigen (PSA) and cleaved in the prostate was formulated for clinical use. The i.v. formulation and manufacture of this peptide conjugate posed several challenges. The main…

expand abstract